Scholarlink

Purpose <p>Technical improvements over the last few years regarding administration of locally ablative radiotherapy to oligometastatic (OMD) and oligoprogressive (OPD) disease in breast cancer has created increased interest. This article gives an overview of the current situation from the perspective of a&#xa0;radiation oncologist.</p> Findings <p>Stereotactic radiotherapy (SBRT) is the most common form for applying ablative radiotherapy doses in metastases-directed therapy (MDT) to oligometastatic or oligoprogressive sites in breast cancer. To the present day, the literature mainly consists of retrospective or nonrandomized trials with mixed results. Nevertheless, there is a&#xa0;growing number of prospective randomized and phase&#xa0;III trials which will soon give us more data in this promising field.</p> Conclusion <p>With growing interest in treating patients with OMD or OPD in a&#xa0;curative intent, locally ablative therapies are gaining more importance. SBRT is a&#xa0;feasible modality with very good results in local disease control and a&#xa0;low toxicity profile and therefore a&#xa0;promising option for treating breast cancer patients with OMD or OPD. Nevertheless, current data does not yet back the routine use, with more prospective data expected soon. Until then, treatment options for those patients should be discussed individually.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Oligometastatic breast cancer from the perspective of the radiation oncologist

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年1月16日

查看全文
  • Stefan Konrad

摘要

Purpose

Technical improvements over the last few years regarding administration of locally ablative radiotherapy to oligometastatic (OMD) and oligoprogressive (OPD) disease in breast cancer has created increased interest. This article gives an overview of the current situation from the perspective of a radiation oncologist.

Findings

Stereotactic radiotherapy (SBRT) is the most common form for applying ablative radiotherapy doses in metastases-directed therapy (MDT) to oligometastatic or oligoprogressive sites in breast cancer. To the present day, the literature mainly consists of retrospective or nonrandomized trials with mixed results. Nevertheless, there is a growing number of prospective randomized and phase III trials which will soon give us more data in this promising field.

Conclusion

With growing interest in treating patients with OMD or OPD in a curative intent, locally ablative therapies are gaining more importance. SBRT is a feasible modality with very good results in local disease control and a low toxicity profile and therefore a promising option for treating breast cancer patients with OMD or OPD. Nevertheless, current data does not yet back the routine use, with more prospective data expected soon. Until then, treatment options for those patients should be discussed individually.